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Summary: A competitive enzyme immunoassay was developed to determine chondroitin-6-sulphate in body fluids
and cell cultures. The assay uses a monoclonal anti-chondroitin-6-sulphate antibody, immobilised to microtitre
plates, and it involves a competitive binding reaction between chondroitih-6-sulphate in the samples and the biotiny-
lated antigen.
This assay enables the quantification of chondroitin-6-sulphate in the low concentration ränge of 16—120 g/l. The
intra-assay and inter-assay coefficients of Variation are below 6.5% and 9.0%, respectively. More than 90% of
chondroitin-6-sulphate was recovered when added to 0.1 mol/1 phosphate-buffered saline, an albumin solution
(40 g/l in phosphäte-buffered saune) and cell culture medium (containing 100 ml/l foetal calf serum).
Chondroitin-6-sulphate was also determined in sera of healthy male (n = 90) and female (n = 90) blood donors.
The normal ränge was 55—169 g/l. In men the mean value was estimated at 102.2 ±37.1 g/l and in women at
98.7 i 26.4 g/l. Np age or sex dependence was observed.
The urine excretion of chondroitin-6-sulphate in men (n = 16) was 44.5 ±21.1 mg/kg creatinine (mean ± Standard
deviation) and in fernales (n = 10) 53.5 ± 21.3 mg/kg creatinine. The clearance rate in men was 0.41 ± 0.22
ml X min"1 and in women €.38 ± 0.15 ml X min"1. No sex dependence was found.
Furthermore, the enzyme immunoassay was modifted to measure the specific incorporation of a radioactively lab-
elled precursor ([14C]galactosamine) into chondroitin-6-sulphate. This modification rapidly gives Information on
the cellular glycosaminoglycan synthesis in cell culture. Usmg this method our experiments with cultivated human
chondrocytes showed that the synthesis of chpndroitin^o-sulphate decreased in the presence of interleukin-la
(60.0% less), turnour necrosis factor a (64.4%), -interferön (21.6%) and lipopolysaccharide (53.4%).
Introduction attached to a core protein to form proteoglycans. The
macromolecule is synthesised in the Golgi apparatus,
Chondroitin sulphate consists of repeated disaccharide transported to the ceil surface and secreted into the ex-
units containing N-acetyl-jD-galactosamine and Z)-glu- tracellular space (2). Chondroitin sulphate is a major and
curonic acid. This glycosaminoglycan is sulphated either ubiquitous component of the extracellular matrix of con-
on the C4 or C6 position of the amino sugar (1) and nective tissues (1). Several methods for the determi-
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nation of chondroitin sulphate have been described.
These techniques use enzymatic digestion, precipitation
and Chromatographie methods, especially high perform-
ance liquid chromatography (3,4).
Methods have been reported recently, which use specific
antibodies against different components of proteogly-
cans (e.g. keratan sulphate, dermatan sulphate) (5-8).
So far, an enzyme immunoassay of chondroitin sulphate
has not been described. The assay described here uses a
monoclonal anti-chondroitin-6-sulphate antibody (9) and
involves a competitive binding reaction between chond-
roitin-6-sulphate in the sample and biotinylated chon-
droitin-4-sulphate s labelled antigen. This enzyme
immunoassay enables the determination of chondroitin-
6-sulphate in serum, urine and cell culture medium.
Materials and Methods
Materials
Bovine serum albumin was obtained frorn Merck, Darmstadt.
Tween 20, o-phenylenediamine, l-ethyl-3-(3-dimethylaminopro-
pyl)-carbodiimide, monoclonal anti-chondroitin-6-sulphate anti-
body (CS 56), adipic acid dihydrazide and N-hydroxysuccinim-
idobiotin were purchased from Sigma, Deisendorf. Streptavidin-
coupled horse radish peroxidase1) was firom Boehringer,
Mannheim, and chondroitinase ABC1) from Seikagaku, Tokyo.
Maxisorb immunoplates were obtained from Nunc, Wiesbaden.
Chondroitin-6-sulphate and chondroitin-4-sulphate were obtained
from Medac, Hamburg and from Sigma, Deisendorf. All chemicals
used were of analytical grade or the highest commercially avail-
able grade.
Methods
Prepara on of biotinylated antigen
Chondroitin sulphate (500 mg) was dissolved in 3 ml adipic acid
dihydrazide (40 g/l, pH 4.75) and shaken for 30 min at room tem-
perature. The solution was incubated for l hour at 4°C with 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide in a ratio of l : 100
by vol. After dialysis, 2 g/l N-hydroxysuccinimidobiotin were ad-
ded and the solution was incubated for 2 hours. After further dialy-
sis the biotinylated antigen was stored at -20 °C.
Enzyme immunoassay
The wells of a plastic microtitre plate were coated overnight at 4 °C
with the anti-chondroitin-6-sulphate antibody (50 μΐ/well, l : 2000
dilution of the ascitic fluid in 0.1 mol/1 phosphate-buffered saline
(8.0 g/l NaCl, 0.2 g/l KC1, 0.2 g/l KH2PO4, 1.1 g/l K2HPO4, pH
7.4)) overnight at 4 °C. The coating solution was removed and the
plates were washed three times with phosph te-buffered saline and
blocked with bovine serum albumin (2 g/l phosphate-buffered sa-
line, 100 μΐ/well) at room temperarure for l hour. Samples (50
μΐ/well) or chondroitin-6-sulphate Standard diluted in phosphate-
buffered saline-Tween were added. After incubation for two hours
at 4 °C, 50 μΐ of the biotinylated antigen were added to each well
for l hour at 4 °C. The wells were washed three times with phos-
phate-buffered saline-Tween, then 50 μΐ streptavidin horse-radish
peroxidase (60 U/l) were added and the solution was incubated for
one hour at 4 °C. The wells were washed with phosphate-buffered
saline and incubated with 50 μΐ of freshly prepared -phenylenedi-
amine (60 g/l) at room temperature for 45 minutes. The enzymatic
colour development was stopped by adding 50 μΐ 0.5 mol/1 sulph-
uric acid and the absorbance was measured at 492 nm with a
Behring microtitre enzyme immunoassay reader.
Analysis of chondroitin sulphates by high performance
liquid chromatography
The chondroitin-6-sulphate used s Standard and the chondroitin-
4-sulphate used s biotinylated antigen were anaiysed by high per-
formance liquid chromatography to deterrnine the composition of
unsaturated chondroitin-suiphate disaccharide. The HPLC analysis
of the disaccharide was carried out according to a modified method
of E. Gurr et al. (4).
Modifica on ofthe enzyme immunoassay to determine the
chondroitin-6-sulphate synthesis ofcultured cells by monitoring
[l4C]galactosamine incorporation
The concentration of l4C^labelled chondroitin^6-sulphate in the
medium of c ltured human chondrocytes was measured by the en-
zyme immunoassay s described above. In a parallel experiment,
after the competitive binding reaction, the microtitre wells were
incubated with trypsin (3 g/l) to detach the l4C-labelled antigen/
antibody complex from the microtitre plates. This enzymatic diges^
tion enabled quantification of radioactivity in a scintillation well.
This method will be published elsewhere (10).
Recovery, precision and detection limit of the enzyme
immunoassay
The accuracy ofthe enzyme immunoassay was investigated by ad-
ding a constant amount of chondroitin-6-sulphate (60 mg) to 0.1
mol/1 phosphate-buffered saline, to an albumin solution (40 g/I in
phosphate-buffered saline), and to a cell culture medium (contain-
ing 100 ml/l foetal calf serum). The concentration of chondroitin-
o^sulph te was determined before and fter addition, and the recov-
ery was calculated.
Different concentrations of chondroitin-6^sulphate (20, 80 and 120
μg/l) were used to determine the inter-assay (n = 70) and intra^-
assay (n = 15) Variation coefficients.
To determine the detection limit of the enzyme immunoassay,
chondroitin-6-sulphate was added in concentrations of 0, 4, 8 and
16 μg/l to 0.1 mol/1 phosphate-buffered saline and to an albumin
solution (40 g/l in phosphate-buffered saline). The low 3s-iimit
(x-3s) of the chondroitin-6-sulphate-free samples was calculated
after a series of 48 determinations. The lowest chondroitin-6-sul-
phate concentration (mean of 48 determinations), which was sig-
nificantly different from this calculated value, was defined s the
detection limit.
Sample preparation
1. Venous blood was obtained from healthy male (n = 90) and
female (n = 90) donors aged 18-65. After clotting, followed by
centrifugation for 10 minutes at 4000 min"1, the serum was frozen
and stored until use.
]) Enzymes:
Chondroitinase ABC EC 4.2.2.4
Horse-radish peroxidase EC l. 11. l .7
2. The urine collection started in the moming by rejecting the
vious night urine and finished after 24 hours by including the sub-
sequent night urine. This urine collection avoids any influence of
circadian rhythm effects on the chondroitin-6-sulphate determi-
nation. Urine from 16 healthy male and 10 -healthy female volun-
teers were tested.
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3. Human chondrocytes were precultivated s a monolayer for 24
hours in Dulbecco's modified Eagles medium supplemented with
heat-inactivated foetal calf semm (50 ml/l), antibiotics and me-
diators. After 24 hours, fresh medium containing the mediators and
[l4C]glucosamine hydrochloride 56 MBq/I was added. The culture
media were collected and the chondroitin-6-sulphate concentration
and specific incorporation rates were determined. The following
mediator concentrations were used: interleukin-ΐα (lO4 U/l), tu-
mour necrosis factor α (100 μg/l), γ-interferon (2 · l O5 U/l) and
lipopolysaccharide (10 μg/l). The mediator concentrations were
chosen accord ig to dose-response studies in which the efficacy of
these concentrations was demonstrated (10).
Stat ist ical analysis
The signrficance of the mean value difference and the age and sex
dependence of chondroitin-6-sulphate were calculated using Stud-
ent's t test and linear correlation analysis, respectively.
Results
Analysis of chondroitin-6-sulphate and
chondroitin-4-sulphate by high performance
liquid chromatography
The chondroitin-6-sulphate used s a Standard contained
78.3% chondroitin-6-sulphate and 21.7% chondroitin-4-
sulphate. The dose response curve of the enzyme
immunoassay was established on the basis of the amount
of chondroitin-6-sulphate in the Standard. The compo-
sition of chondroitin-4-sulphate was 89.5% chondroitin-
4-sulphate, 4.5% chondroitin-6-sulphate and 6% non-
sulphated chondroitin (chondroitin-0-sulphate).
Biotinylatio of antigens
The binding affi'nity of the biotinylated chondroitin-6-
sulphate and biotinylated chondroitin-4-sulphate to the
monoclonal antibody was investigated. The antigenicity
of chondroitin-6-sulphate was considerably reduced
after biotinylation (fig. 1). Despite several modifications
of the biotinylating reaction it was not possible to in-
crease the antigenicity of biotinylated chondroitin-6-sul-
phate. However, the antigenicity of chondroitin-4-sul-
phate was not influenced by biotinylation, so this was
used s the competitive antigen in an optimal concen-
tration of 100 mg/l.
Dose response c rve of the enzyme
immunoassay
The dose response curve of the enzyme immunoassay
was obtained by using the biotinylated chondroitin·^
s lphate s competitive antigen (fig. 2). Corresponding
Standard curves were obtained using 0.1 mol/I phos-
phate-buffered saune and albumin (40 g/l in 0.1 mol/1
phosphate-buffered salme). In addition, the Standard
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Fig. l Binding of biotinylated chondroitin-6-sulphate (O-O) and
biotinylated chondroitin-4-sulphate (o-o) to the monoclonal anti-
chondroitin-6-sulphate antibody. The labelled chondroitin sulphates
were added in different concentrations to the anti-chondroitin-6-
sulphate antibody. The antigen-antibody complex was incubated
with streptavidin horse-radish peroxidase and the absorbance at
492 nm was measured after Substrate addition.
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Fig. 2 Dose-response curve of the chondroitin-6-sulphate enzyme
immunoassay in different matrices: 0.1 mol/1 phosphate-buffered
saline (O-O) and albumin (40 g/l) (o-·). Mean value and Stan-
dard deviation of 48 determinations are given.
ml/l) showed a similar course. The linearity of the dose
response curve was found at a concentration of 16-120
μ§/1. Matrix effects were observed only at a chondroitin-
6-sulphate concentration of 80 μ^Ι. The difference be-
tween the phosphate-buffered saline Standard curve and
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the albumin Standard curve was 8%. However, the dif-
ference was within the Standard deviation. At all other
concentrations the differences were less than 5%.
Cross-reactivity of the enzyme irnmunoassay
with other glycosaminoglycans
Cross-reactivity is defined äs 50% Inhibition of binding
of glycosaminoglycans to the monoclonal antibody. The
50% Inhibition point of chondroitin-6-sulphate was
found at 27 g/l. The concentration of chondroitin-4-
sulphate required for 50% Inhibition was 112 g/l, i.e.
about 4000 times greater than that required for the
equivalent Inhibition by chondroitin-6-suiphate. The
cross-reaction of other glycosaminoglycans was con-
siderably outside the linear ränge of chondroitin-6-sul-
phate (fig. 3). The concentrations of these glycosamino-
glycans causing 50% Inhibition were: dermatan sulphate
l g/l, keratan sulphate > l g/l, hyaluronan > 5 g/l, arid
heparin > 10 g/l.
'. N
Precision, recovery and detection limit of the
chondroitin-6-sulphate irnmunoassay
The inter-assay and intra-assay Variation coefficients are
less than 9.0% and 6.5%, respectively (fig. 4). The re-
covery of chondroitin-6-sulphate was in the ränge of
87.5%-109.6% (tab. 1). The detection limit was 16
(tab. 2).
0 0.0001 0.001 0.01 0.1 1 10 100
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Fig. 3 Dose-response curves of the monoclonal anti-chondroitin-
6-sulphate antibody with different glycosaminoglycans. The cross^
reactivities defined äs the glycosaminoglycan concentration at 50%
Inhibition were calculated: chondroitin-6-sulphate (·-·): 27 jjg/1;
chondroitin-4-sulphate (O-O): 112 mg/1; dermatan sulphate
(D-b): l g/l; keratan sulphate (D-D): > l g/l; hyaluronan (A- A):
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Fig. 4 Imprecision of the enzyme immunoassay. The intra-assay
(n =^ 15) (o-o) and inter-assay (n = 70) (Q-O) Variation coef-
ficients of different choiidroitirUö-sulphate concentrations are
given.
Tab. l Determination of chondroitin-6-sulphate in the presence
of differerit matrices and recovery of exogenously added chondro-
itin-6-sulphate. The experiments were carried out in quadruplicate.



































Concentration of chondroitin-6-sulphäte iri
blood serum
The normal ränge of chondroitin-6-sulphate in blood
seriim was 55 — 169 §/1. In the serum of healthy males
the mean chondroitin-6-sulphate concentration was 101
§/1 (95% ränge: 56-169 pg/l) and in females 99 g/l
(95% ränge: 61-150 g/l). No sex ör äge dependeüce
was found (fig. 5). · J
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Tab. 2 Evaluation of the detection limit of the enzyme immuno-
assay. The absorbance of the enzyme immunoassay was measured
using samples with and without small amounts of chondroitin-6-
sulphate in 0.1 mol/1 phosphate-buffered saune and in albumin
(40 g/l). Mean values (X) and Standard deviations (s) are given. The
low 3s-limit (K-3s) of a chondroitin-6-sulphate-free sample was
calculated after a series of 48 determinations. The lowest chondro-
itin-6-sulphate concentration (mean of 48 determinations), which
was significantly different from this calculated value, was defmed









































Fig. 5 Chondroitin^6rsülphate concentration in the serum of male
(O) and female (·) bloöd donors of different ages. The means of
each age group (n ̂  10) are given for male (D—D) and female
(D-B).
Concentration of chondroitin*6-sulphate in
urine
The urine conoentration of chondroitin-6-sulphate in
males was 44.5 * 21.1 mg/kg creatinine (mean ± Stan-
dard deviation) and in females 53; 5 ±21.3 mg/kg creat-
inine. The chondroitin-6-sulphate clearance in inen was
determined äs 0.41 ±. 0.22 ml X min"1 and in women
äs 0.38 ± 0.15 ml X min"1. No sex dependence was ob-
served.
Determination of chondroit in-6-sulphate
synthesis rate in chondrocyte culture by
modificätion of the enzyme immunoassay
The synthesis of chondroitin-6-sulphate was investigated
in the medium of human chondrocytes cultivated with
and without agents. The incorporation of I4C-labelled
galactosamine into chondroitin-6-sulphate was used äs a
specific index of the synthesis rate. In comparison with
chondrocytes incubated without agents, the chondroitin-
6-sulphate synthesis decreased in the presence of the fol-
lowing agents: tumour necrosis factor (TNF a):
64.4%, interleukin-la (IL-la): 60.0%, bacterial lipopo-
lysaccharide (LPS): 53.4%, and -interferon ( -INF):
21.6%(tab.3).
Discussion
Development of an enzyme immunoassay for chondro-
itin-6-sulphate was made difficult by the availability of
only one monoclonal IgM antibody against chondroitin-
6-sulphate. We therefore used a competitive method. In
our assay, a biotinylated chondroitin-4-sulphate antigen
competes with the antigen in the sample for the binding
sites of the antibody which was immobilised on the plas-
tic surface of the microtitre plate.
Tab. 3 Measurement of [14C]galactosamine incorporation in
chondroitin-6-sulphate by modificätion of the enzyme immuno-
assay. After the determination of the concentration of chondroitin-
6-sulphate in the culture medium, the chondroitin-6-sulphate anti-
body complex was enzymatically detached from the microtitre
plates and the radioactivity of the [14C]chondroitin-6-sulphate was
measured. The calculation of the [14C]chondroitin-6-sulphate pro-
vides a specific value related to the synthesis rate of this glycosami-
noglycan. This is shown in studies with human chondrocyte cul-
tures incubated with different agents for 48 höurs. Agent concen-
trations: interleukin-la: l O4 U/l; tumour necrosis factor a: 100
g/l; -interferon: 2 · l O5 U/l; lipopolysaccharide: 10 g/l; [l4C]ga-
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Difterent procedures were tested to optimise the biotin-
ylation of chondroitin sulphate, since it was observed
that the antigenicity of the modified chondroitin-6-sul-
phate had been altered. The monoclonal anti-chondro-
itin-6-sulphate antibody recognised the biotinylated
chondroitin-6-sulphate to a lesser extent than it did the
native form. The decreased antigenicity of biotinylated
chondroitin-6-sulphate may be due to steric effects of
the sulphate position. In contrast, the antigenicity of
biotinylated chondroitin-4-sulphate was unchanged.
Consequently, the biotinylated chondroitin-4-sulphate
was used äs a competitive aritigen at a concentration of
100 mg/1 and reproducible dose response curves were
obtained for the determination of chondroitin-6-sulphate
in body fluids and cell culture media. Our method avoids
the use of radiolabelled ligands and, by using enzyme
immunoassay plates, has proved itself to be a rapid and
efficient technique.
The biochemistry of cartilage destruction in inflamma-
tory and degenerative joint disease has been extensively
studied, arid it has been found that the loss of proteogly-
cans of the extracellular matrix is one of the earliest
events during the pathobiochemical process (11 — 13).
Thus, the measurement of proteoglycans and their cata-
bolic products in synovial fluid and serum may provide
usefiil diagnostic markers for joint diseases. However,
the majority of glycosaminoglycans are ubiquitous inter-
cellular matrix components of different connective tis-
sues. It has been suggested that keratan sulphate is a
more specific analyte, since it mainly originates frorn
cartilage and, to a lesser extent, from the cornea and
aorta (1). Therefore, antibodies against these glycosami-
noglycans were developed and used in several immunol-
ogical assays. In some studies it has been reported that
patients with osteoarthritis showed a significantly higher
serum concentration of keratan sulphate than healthy
volunteers. However, there is still considerable contro-
versy äs to whether the serum concentration of keratan
sulphate is a specific indication of cartilage destruction
(8, 14-15).
Chondroitin-6-sulphate is a glycosaminoglycan, which
may also be used äs a diagnostic factor in connective
tissue diseases, including intracellular degradation of
connective tissue and the metabolic activity of connec-
tive tissue cells during repair processes. However, the
diagnostic relevance of this quantity must be elucidated
in further investigations.
The synovial cell culture reproSents a defined mödel for
obtaining Information on the metabolism of chondroitin
sulphate in the synovial System and for investigätirig the
influence of different agents on the metabolism of this
glycosaminoglycan. In studies on the synthesis Of chon-
droitin sulphate the incorporation of radiolabelled galac-
tosamine into the glycosamirioglyean is usüally deter-
mined. However, measurement of radiolabelled chond-
roitin sulphate isolated from cell culture medium may
lead to oversimplification of the Interpretation, because
changes in the measured chondroitin sulphate concen-
tration in the medium can be influenced by partial Steps
of metabolism, such äs intracellular synthesis, secf etion
into the medium, re-uptake of the macromolecule and
intracellular degradation. One unsatisfäctory way which
has been used to overcome this problem is the simul-
taneous investigation of the concentration of chondro-
itin-6-sulphate in the extra-, peri- or intracellular pool
(16). The new enzyme immunoassay of chondroitin-6-
sulphate, in combination with the assay of the antibody
bound to 14C-labelled choiidroitin-6-sülphate, riöw en-
ables measurement of the specific incorporation of
[14C]galactosamine into chondroitin-6-sulphate äs a
means of quantifying the synthesis rate of this glycos-
aminoglycan. Therefore, amplification of the enzyme
immunoassay in this way represents a useful tool for
obtaining rapid Information on the synthesis of chon-
droitin-6-sulphate in cell culture (10).
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